Universitätsklinikum Würzburg

DIFFUSING CAPACITY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS (2017) Moinzadeh P, Blank N, Siegert E, Henes J, Worm M, Sunderkoetter C, Schmalzing M, et al. Conference contribution Can checkpoint inhibitor therapy improve response to chemotherapy? (2017) Boßerhoff AK, Schuler G, Heinzerling L, Schilling B, Haferrkamp S, Kirchberger M Conference contribution, Conference Contribution SOP - Dealing with multidrug-resistant pathogens on the palliative care unit (2017) Ostgathe C, Stachura P, Hofmann S, Van Oorschot B, Oechsle K, Bogdan C, Kunz HB, et al. Journal article Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients (2017) Cosgarea , Zimmer L, Weide B, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, et al. Conference contribution A novel human artery model to assess the magnetic accumulation of SPIONs under flow conditions (2017) Janikowska A, Matuszak J, Lyer S, Schreiber E, Unterweger H, Zaloga J, Groll J, et al. Journal article Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study (2017) Scheller C, Wienke A, Tatagiba M, Gharabaghi A, Ramina KF, Ganslandt OT, Bischoff B, et al. Journal article Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation (2017) Oehler B, Kistner K, Martin C, Schiller J, Mayer R, Mohammadi M, Sauer RS, et al. Journal article Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry (2017) Gassenmaier M, Eigentler TK, Keim U, Goebeler M, Fiedler E, Schuler G, Leiter U, et al. Journal article Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma (2017) Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kaehler KC, et al. Journal article Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity (2017) Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, et al. Journal article